Efficacy and Treatment Satisfaction of Different Systemic Therapies in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study

Efficacy and Treatment Satisfaction of Different Systemic Therapies in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study

For the treatment of moderate-to-severe atopic dermatitis in children and adolescents, the monoclonal antibody dupilumab and the selective JAK-1 inhibitor upadacitinib are two modern systemic therapies approved for long-term treatment. Both drugs have demonstrated high efficacy in randomized control...

Full description

Bibliographic Details
Main Authors: Sebastian Kiefer, Anke König, Viviane Gerger, Christine Rummenigge, Anne Christine Müller, Thomas Jung, Alexandra Frank, Georgios Tassopoulos, Emilie Laurent, Roland Kaufmann, Andreas Pinter
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Journal of Clinical Medicine
Subjects:
atopic dermatitis
children
adolescents
dupilumab
upadacitinib
real-world data
Online Access:https://www.mdpi.com/2077-0383/12/3/1175

Internet

https://www.mdpi.com/2077-0383/12/3/1175

Similar Items